Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Galtier

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Haematologica|April 23, 2026
Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experienceGaetan Basile, Arnaud Neuville, Delphine Martineau, et al.
Haematologica|June 9, 2022
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cellsJean Galtier, Laetitia Vercellino, Loic Chartier, et al.
Blood Advances|May 1, 2025
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomasPierre Stephan, Roberta Di Blasi, Louise Roulin, et al.
Blood Advances|August 14, 2020
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcomePierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
American Journal of Hematology|November 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registriesChristian Récher, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood|September 3, 2021
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experienceAlexis Caulier, Murielle Roussel, Pierre Morel, et al.
Hemasphere|February 19, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registryJean Galtier, Charles Mesguich, Pierre Sesques, et al.
European Journal of Cancer (Oxford, England : 1990)|November 7, 2024
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelinesCédric Rossi, Guillaume Manson, Amira Marouf, et al.
Transplantation and Cellular Therapy|February 27, 2023
Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TCEléonore Kaphan, François Bettega, Edouard Forcade, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2025
Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelinesLoïc Renaud, Marie Donzel, Justine Decroocq, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Haematologica|April 23, 2026
Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experienceGaetan Basile, Arnaud Neuville, Delphine Martineau, et al.
Haematologica|June 9, 2022
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cellsJean Galtier, Laetitia Vercellino, Loic Chartier, et al.
Blood Advances|May 1, 2025
TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomasPierre Stephan, Roberta Di Blasi, Louise Roulin, et al.
Blood Advances|August 14, 2020
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcomePierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
American Journal of Hematology|November 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registriesChristian Récher, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood|September 3, 2021
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experienceAlexis Caulier, Murielle Roussel, Pierre Morel, et al.
Hemasphere|February 19, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registryJean Galtier, Charles Mesguich, Pierre Sesques, et al.
European Journal of Cancer (Oxford, England : 1990)|November 7, 2024
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelinesCédric Rossi, Guillaume Manson, Amira Marouf, et al.
Transplantation and Cellular Therapy|February 27, 2023
Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TCEléonore Kaphan, François Bettega, Edouard Forcade, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2025
Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelinesLoïc Renaud, Marie Donzel, Justine Decroocq, et al.
Pageof 3